Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tesaro has got worldwide license to develop, manufacture, commercialize and distribute small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK) from Amgen.
Subscribe to our email newsletter
Tesaro intends to discover compounds for oncology indication as well as for the treatment of the patients with non-small cell lung cancer (NSCLC) whose tumors are ALK-positive.
The agreement covers an upfront payment, potential future payment and royalties associated with the achievement of certain development and commercial milestones.
Tesaro president and chief scientific officer Mary Lynne Hedley said Tesaro is very pleased to announce this license agreement and intends to rapidly complete the necessary studies and activities required for submission of an IND application and advance this promising therapeutic for cancer patients to clinical phase testing.